XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table represents Evolent’s revenue disaggregated by end-market and product type:
For the Three Months Ended March 31,
20232022
Medicaid$183,034 $130,501 
Medicare127,669 104,399 
Commercial and other116,987 62,157 
Total$427,690 $297,057 
Performance Suite$239,873 $171,164 
Specialty Technology and Services Suite65,316 13,580 
Administrative Services83,067 106,859 
Cases39,434 5,454 
Total$427,690 $297,057 
Schedule of Contract with Customer, Asset and Liability
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of March 31, 2023 and December 31, 2022 (in thousands):
March 31, 2023December 31, 2022
Short-term receivables (1)
$261,875 $246,209 
Short-term deferred revenue7,069 5,758 
Long-term deferred revenue2,193 2,533 
————————
(1)Excludes pharmacy claims receivable and premiums receivable.

Changes in deferred revenue for the three months ended March 31, 2023, are as follows (in thousands):
Deferred revenue
Balance as of beginning-of-period$8,291 
Reclassification to revenue, as a result of performance obligations satisfied(3,987)
Cash received in advance of satisfaction of performance obligations4,958 
Balance as of end of period$9,262